ARQTArcutis Biotherapeutics, Inc.

Nasdaq arcutis.com


$ 8.12 $ 0.14 (1.75 %)    

Tuesday, 14-May-2024 15:59:55 EDT
QQQ $ 445.88 $ 2.85 (0.64 %)
DIA $ 395.58 $ 1.12 (0.28 %)
SPY $ 523.16 $ 2.39 (0.46 %)
TLT $ 90.86 $ 0.51 (0.56 %)
GLD $ 218.12 $ 1.83 (0.85 %)
$ 8.13
$ 8.15
$ 0.00 x 0
$ 0.00 x 0
$ 8.01 - $ 8.24
$ 1.76 - $ 13.17
4,658,048
na
902.82M
$ 0.42
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 02-27-2024 12-31-2023 10-K
3 11-03-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 02-28-2023 12-31-2022 10-K
7 11-08-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-05-2022 03-31-2022 10-Q
10 02-22-2022 12-31-2021 10-K
11 11-04-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 02-16-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-11-2020 06-30-2020 10-Q
17 05-12-2020 03-31-2020 10-Q
18 03-19-2020 12-31-2019 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 arcutis-biotherapeutics-stock-climbs-after-blockbuster-q1-results

Arcutis Biotherapeutics reports its first-quarter financial results after the bell Tuesday.

 arcutis-biotherapeutics-q1-2024-adj-eps-032-beats-073-estimate-sales-4957m-beat-1468m-estimate

Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly earnings of $0.32 per share which beat the analyst consensus estimate ...

 the-journal-of-clinical-and-aesthetic-dermatology-published-arcutis-biotherapeutics-outcomes-of-a-comprehensive-evaluation-by-an-expert-dermatologist-panel-assessing-the-formulation-ingredients-of-zoryve-topical-foam-03

Eight of nine experts expressed feeling "extremely confident" about prescribing ZORYVE foam to patients of diverse skin...

 needham-reiterates-buy-on-arcutis-biotherapeutics-maintains-16-price-target

Needham analyst Serge Belanger reiterates Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and maintains $16 price target.

 eqt-genie-energy-and-other-big-stocks-moving-lower-on-monday

U.S. stocks were lower, with the Dow Jones index falling more than 150 points on Monday.

 arcutis-announces-acceptance-of-late-breaking-abstract-in-atopic-dermatitis-among-five-new-topical-roflumilast-data-being-presented-at-the-american-academy-of-dermatology-annual-meeting

Late breaking sessions to highlight new data from the INTEGUMENT-PED trial evaluating roflumilast cream 0.05% in children ages ...

 arcutis-prices-150m-public-offering-of-15789474-common-shares-at-950share

The gross proceeds to Arcutis from the offering are expected to be approximately $150.0 million, before deducting underwriting ...

 arcutis-and-sato-announce-strategic-collaboration-and-licensing-agreement-for-topical-roflumilast-in-japan-the-arcutis-to-receive-a-25m-upfront-payment-and-is-eligible-to-receive-potential-development-and-commercial-milestone-payments-totaling-40m

Arcutis to receive a $25 million upfront payment, and is eligible to receive potential development and commercial milestone pay...

 goldman-sachs-maintains-neutral-on-arcutis-biotherapeutics-raises-price-target-to-11

Goldman Sachs analyst Jonathan Block maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Neutral and raises the price tar...

 mizuho-reiterates-buy-on-arcutis-biotherapeutics-raises-price-target-to-17

Mizuho analyst Uy Ear reiterates Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $16 to $17.

 needham-maintains-buy-on-arcutis-biotherapeutics-raises-price-target-to-16

Needham analyst Serge Belanger maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $...

 arcutis-biotherapeutics-q4-2023-gaap-eps-072-beats-076-estimate-sales-1353m-beat-1134m-estimate

Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate ...

 arcutis-biotherapeutics-q4-gaap-eps-072-beats-078-estimate-sales-1353m-beat-1134m-estimate

Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate ...

 earnings-scheduled-for-february-27-2024

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on rev...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION